Stock-Based Compensation (Tables)

3 Months Ended

Oct. 31, 2023

Share-Based Payment Arrangement [Abstract]

Summary of stock-based awards outstanding by award type

As of October 31, 2023, the following stock-based awards, by award type, were outstanding:

	October 31, 2023
Stock options	234,260
Performance shares	827,802
RSUs, restricted stock, share units and other stock-based awards	1,624,324
Total	2,686,386

Stock-based compensation for awards detailing where recorded in Consolidated Statement of Operations

Stock-based compensation for awards issued is reflected in the following line items in our Condensed Consolidated Statements of Operations:

	Three months ended October 31,
	2023		2022
Cost of sales	$	282,000	158,000
Selling, general and administrative expenses	2,176,000		648,000
Research and development expenses	187,000		98,000
Stock-based compensation expense before CEO transition costs	2,645,000		904,000
CEO transition costs related to equity-classified stock-based awards	—		3,764,000
Total stock-based compensation expense before income tax benefit	2,645,000		4,668,000
Estimated income tax benefit	(584,000)		(493,000)
Net stock-based compensation expense	$	2,061,000	4,175,000

Summary of stock-based compensation expense by award type

Stock-based compensation expense, by award type, is summarized as follows:

	Three months ended October 31,
	2023		2022
Stock options	$	19,000	25,000
Performance shares	357,000		74,000
RSUs, restricted stock and share units	2,244,000		774,000
ESPP	25,000		31,000
Stock-based compensation expense before CEO transition costs	2,645,000		904,000
CEO transition costs related to equity-classified stock-based awards	—		3,764,000
Total stock-based compensation expense before income tax benefit	2,645,000		4,668,000
Estimated income tax benefit	(584,000)		(493,000)
Net stock-based compensation expense	$	2,061,000	4,175,000

Summary of the Plan's activity relating to stock options

The following table summarizes the Plan’s activity:

	Awards (in Shares)	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding at July 31, 2023	240,510	$	23.96
Expired/canceled	(6,250)	24.31
Outstanding at October 31, 2023	234,260	$	23.95	3.82	$	—
Exercisable at October 31, 2023	206,880	$	24.75	3.46	$	—
Vested and expected to vest at October 31, 2023	233,021	$	23.98	3.81	$	—

Summary of the Plan's activity relating to performance shares, RSUs, restricted stock and share units

The following table summarizes the Plan’s activity relating to performance shares, RSUs, restricted stock, share units and other stock-based awards:

	Awards (in Shares)	Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
Outstanding at July 31, 2023	1,876,230	$	13.21
Granted	913,908	9.93
Settled	(296,198)	16.03
Canceled/Forfeited	(41,814)	15.80
Outstanding at October 31, 2023	2,452,126	$	11.60	$	29,916,000
Vested at October 31, 2023	774,430	$	12.98	$	9,448,000
Vested and expected to vest at October 31, 2023	2,380,255	$	11.62	$	29,039,000